Differences between rat primary cortical neurons and astrocytes in purine release evoked by ischemic conditions.
In the brain, the levels of adenosine increase up to 100-fold during cerebral ischernia; however, the roles of specific cell types, enzymatic pathways and membrane transport processes in regulating intra- and extracellular concentrations of adenosine are poorly characterized. Rat primary cortical neurons and astrocytes were incubated with [(3)H]adenine for 30 min to radiolabel intracellular ATP. Cells were then treated with buffer, glucose deprivation (GD), oxygen-glucose deprivation (OGD), 100 micro M sodium cyanide (NaCN) or 500 micro M iodoacetate (IAA) for 1 h to stimulate the metabolism of ATP and cellular release of [(3)H]purines. The nucleoside transport inhibitor dipyridamole (DPR) (10 micro M), the adenosine kinase inhibitor iodotubercidin (ITU) (1 micro M), the adenosine deaminase inhibitor EHNA (1 micro M) and the purine nucleoside phosphorylase inhibitor BCX-34 (10 micro M) were tested to investigate the contribution of specific enzymes and transporters in the metabolism and release of purines from each cell type. Our results indicate that (a). under basal conditions astrocytes released significantly more [(3)H]adenine nucleotides and [(3)H]adenosine than neurons, (b). OGD, NaCN and IAA conditions produced significant increases in [(3)H]adenosine release from neurons but not astrocytes, and (c) DPR blocked [(3)H]inosine release from both astrocytes and neurons but only blocked [(3)H]adenosine release from neurons. These data suggest that, in these experimental conditions, adenosine was formed by an intracellular pathway in neurons and then released via a nucleoside transporter. In contrast, adenine nucleotide release and extracellular metabolism to adenosine appeared to predominate in astrocytes.
Parkinson
F E
FE
Department of Pharmacology and Therapeutics, University of Manitoba, 753 McDermot Avenue, Winnipeg, MB, R3E 0T6 Canada. Fiona_Parkinson@umanitoba.ca
Sinclair
C J D
CJ
Othman
T
T
Haughey
N J
NJ
Geiger
J D
JD
D000227:Adenine Nucleotides / Q000378:metabolism; D058892:Adenosine Deaminase Inhibitors; D000248:Adenosine Kinase / Q000037:antagonists & inhibitors; D000255:Adenosine Triphosphate / Q000502:physiology; D000818:Animals; D000963:Antimetabolites / Q000494:pharmacology; D001253:Astrocytes / Q000187:drug effects / Q000378:metabolism*; D002545:Brain Ischemia / Q000378:metabolism*; D002478:Cells, Cultured; D002540:Cerebral Cortex / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism*; D002855:Chromatography, Thin Layer; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005110:Extracellular Space / Q000187:drug effects / Q000378:metabolism; D005947:Glucose / Q000502:physiology; D019271:Hypoxanthine / Q000378:metabolism; D020925:Hypoxia-Ischemia, Brain / Q000378:metabolism; D007288:Inosine / Q000378:metabolism; D007461:Iodoacetates / Q000494:pharmacology; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D011687:Purines / Q000378:metabolism*; D051381:Rats; D012966:Sodium Cyanide / Q000494:pharmacology
D000227:Adenine Nucleotides; D058892:Adenosine Deaminase Inhibitors; D000963:Antimetabolites; D004791:Enzyme Inhibitors; D007461:Iodoacetates; D011687:Purines; D019271:Hypoxanthine; D007288:Inosine; D000255:Adenosine Triphosphate; D000248:Adenosine Kinase; D005947:Glucose; D012966:Sodium Cyanide